Want to see IN:NATCAPSUQ full AI Analyst Report?
Top Page
Natural Capsules Limited
(NATCAPSUQ)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹178.00
▲(22.63% Upside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance—margin collapse, a shift to net loss, and negative free cash flow that raises funding risk. This is partially offset by strong technical strength with the stock trading above all key moving averages and positive momentum, while valuation remains challenged due to losses (negative P/E) and no stated dividend yield.
Positive Factors
Revenue Expansion
Strong FY2026 revenue expansion indicates the company continued to grow its top line and maintain demand for its products. Although profitability weakened, a larger revenue base can support operating leverage and provide a foundation for recovery if cost and pricing pressures improve.
Negative Factors
Sharp Profitability Deterioration
The shift from near break-even to a sizable net loss is a major deterioration in earnings quality. Material gross-margin compression reduces the profit available from each unit of revenue, making sustained growth less valuable until pricing, mix, or cost pressures are addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
Strong FY2026 revenue expansion indicates the company continued to grow its top line and maintain demand for its products. Although profitability weakened, a larger revenue base can support operating leverage and provide a foundation for recovery if cost and pricing pressures improve.
Read all positive factors
Natural Capsules Limited (NATCAPSUQ) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.80B
Dividend Yield0.4%
Average Volume (3M)7.49K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth8.84%
EPS Growth-285.42%
CountryIN
Employees620
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-6.25
Shares Outstanding10,411,154
10 Day Avg. Volume2,728
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.55
P/FCF Ratio-9.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Natural Capsules Limited Business Overview & Revenue Model
Company Description
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guarantee...
Natural Capsules Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 857.19M | 1.87B | 1.64B |
| Gross Profit | 350.75M | 467.09M | 757.25M |
| EBITDA | 39.63M | 1.72M | 182.22M |
| Net Income | -64.68M | -170.74M | 6.17M |
Balance Sheet | |||
| Total Assets | 4.20B | 4.24B | 4.19B |
| Cash, Cash Equivalents and Short-Term Investments | 53.75M | 48.23M | 51.98M |
| Total Debt | 1.12B | 1.15B | 1.05B |
| Total Liabilities | 1.75B | 1.89B | 1.62B |
| Stockholders Equity | 2.27B | 2.22B | 2.33B |
Cash Flow | |||
| Free Cash Flow | -115.70M | -106.77M | -178.78M |
| Operating Cash Flow | 201.52M | 8.53M | 267.52M |
| Investing Cash Flow | -313.49M | -115.30M | -444.85M |
| Financing Cash Flow | 25.08M | 102.16M | 161.67M |
Natural Capsules Limited Technical Analysis
Neutral
145.15
Price Trends
165.53
Positive
160.85
Positive
163.48
Positive
Market Momentum
5.27
Positive
46.41
Neutral
2.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATCAPSUQ, the sentiment is Neutral. The current price of 145.15 is below the 20-day moving average (MA) of 191.30, below the 50-day MA of 165.53, and below the 200-day MA of 163.48, indicating a neutral trend. The MACD of 5.27 indicates Positive momentum. The RSI at 46.41 is Neutral, neither overbought nor oversold. The STOCH value of 2.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NATCAPSUQ.
Natural Capsules Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.57B | 11.34 | ― | 0.70% | 4.29% | 2.40% | |
60 Neutral | ₹1.80B | 13.64 | ― | ― | -7.71% | 927.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.25B | 35.58 | ― | ― | 0.46% | -83.31% | |
52 Neutral | ₹1.80B | -8.02 | ― | 0.40% | 8.84% | -285.42% | |
49 Neutral | ₹1.63B | 22.57 | ― | 1.17% | 13.51% | -14.80% | |
48 Neutral | ₹2.13B | -0.97 | ― | 20.72% | -99.53% | -41.93% |
* General Sector Average
IN:NATCAPSUQ
Natural Capsules Limited
172.20
-73.85
-30.01%
IN:ALPA
Alpa Laboratories Limited
60.05
-34.58
-36.54%
IN:BALPHARMA
Bal Pharma Limited
100.27
17.23
20.75%
IN:BROOKS
Brooks Laboratories Limited
61.39
-86.56
-58.51%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.01
-5.03
-31.36%
IN:PAR
Par Drugs and Chemicals Limited
136.60
23.93
21.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.